PFE — Pfizer Share Price

As of Today at 18:18 UTC, shares in Pfizer are trading at $50.91. This share price information is delayed by 15 minutes.

Shares in Pfizer last closed at $50.91 and the price had moved by -4.02% over the past 365 days. In terms of relative price strength the Pfizer share price has outperformed the S&P500 Index by +6.99% over the past year.

The overall consensus recommendation for Pfizer is Buy. You can view the full broker recommendation list by unlocking its StockReport.

The Pfizer dividend yield is 3.12% based on the trailing twelve month period.

Last year, Pfizer paid a total dividend of $1.59, and it currently has a trailing dividend yield of 3.12%.Looking ahead, the next dividend pay date is 2022-12-05.

We do not have data on when Pfizer is to next pay dividends.  The historic dividend yield on Pfizer shares is currently 3.12%.

To buy shares in Pfizer you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

As of the previous close price of $50.91, shares in Pfizer had a market capitalisation of $285.77bn.

Here are the trading details for Pfizer: 

• Country of listing: United States
• Exchange: NYQ
• Ticker Symbol: PFE

Based on an overall assessment of its quality, value and momentum Pfizer is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

The analyst consensus target price for shares in Pfizer is $54.78.  That is 7.6% above the last closing price of $50.91.

Analysts covering Pfizer currently have a consensus Earnings Per Share (EPS) forecast of $6.47 for the next financial year.

An important predictor of whether a stock price will go up is its track record of momentum.  Price trends tend to persist, so it's worth looking at them when it comes to a share like Pfizer. Over the past six months, its share price has underperformed the S&P500 Index by -3.14%.

As of the last closing price of $50.91, shares in Pfizer were trading +3.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

The Pfizer PE ratio based on its reported earnings over the past 12 months is 10.02. The shares last closed at $50.91. 

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Pfizer's management team is headed by: 

• Albert Bourla - CHM
• Angela Hwang - CEX
• Payal Sahni - CHO
• Lidia Fonseca - EVP
• Rady Johnson - EVP
• Douglas Lankler - EVP
• William Carapezzi - EVP
• Alexander Mackenzie - EVP
• Aamir Malik - EVP
• Mike Mcdermott - EVP
• Sally Susman - EVP
• Christopher Stevo - SVP
• Mikael Dolsten - CSO
• Shantanu Narayen - LED
• Ronald Blaylock - IND
• Susan Desmond-Hellmann - IND
• Joseph Echevarria - IND
• Scott Gottlieb - IND
• William Gray - IND
• Helen Hobbs - IND
• Susan Hockfield - IND
• Dan Littman - IND
• Suzanne Nora Johnson - IND
• James Quincey - IND
• James Smith - IND